SidaGhanaV1, PascalFrancis, Curation, bibRecord, 000127

Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana

Identifieur interne : 000127 ( PascalFrancis/Curation ); précédent : 000126; suivant : 000128

Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana

Auteurs : Fred Stephen Sarfo [Ghana] ; Adetayo Kasim [Royaume-Uni] ; Richard Phillips [Ghana] ; Anna Maria Geretti [Royaume-Uni] ; David R. Chadwick [Royaume-Uni]

Source :

The Journal of infection [ 0163-4453 ] ; 2014.

RBID : Pascal:14-0264029

Descripteurs français

Pascal (Inist)
- SIDA, Hépatite virale B, Antiviral, Chimiothérapie, Long terme, Antirétroviral, Virus immunodéficience humaine, Ghana.
Wicri :
- geographic : Ghana.

English descriptors

KwdEn :
- AIDS, Antiretroviral agent, Antiviral, Chemotherapy, Ghana, Human immunodeficiency virus, Long term, Viral hepatitis B.

Abstract

Objectives: To observe the long term response to first-line antiretroviral therapy (ART) in HIV and hepatitis B virus (HBV) co-infected patients in Ghana and explore predictors of poor clinical outcomes. Methods: Retrospective cohort study of hepatitis B surface antigen (HBsAg) positive and negative patients receiving predominantly NNRTI-based ART with lamivudine plus either zidovudine or stavudine for up to seven years. Cox proportional hazards and Kaplan Meier survival analyses compared clinical outcomes and identified baseline characteristics predictive of poor outcomes. A mixed effects model compared changes in CD4 counts. Results: A total of 299 HBsAg-positive and 1869 HBsAg-negative patients started ART between 2004 and 2008. Over a median 35 months of follow-up, HBsAg-positive patients were more likely to die or default care than HBsAg-negative patients, aHR 1.36 (95% CI, 1.03-1.80). HBsAg-positive patients were also more likely to develop Grade 3/4 hepatotoxicity than HBsAg-negative patients, HR 1.99 (1.16-3.40) on survival analysis. There was no significant difference in CD4 responses between HBsAg-positive and HBsAg-negative patients. Conclusions: HBsAg-positive patients are at significantly increased risk of adverse clinical outcomes after starting ART. Further studies are warranted to evaluate whether these risks remain now that tenofovir is becoming routinely available in Ghana.

A01	`01`	`1`		`@0 0163-4453`
A02	`01`			`@0 JINFD2`
A03		`1`		`@0 J. infect.`
A05				`@2 69`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana`
A11	`01`	`1`		`@1 SARFO (Fred Stephen)`
A11	`02`	`1`		`@1 KASIM (Adetayo)`
A11	`03`	`1`		`@1 PHILLIPS (Richard)`
A11	`04`	`1`		`@1 GERETTI (Anna Maria)`
A11	`05`	`1`		`@1 CHADWICK (David R.)`
A14	`01`			`@1 Komfo Anokye Teaching Hospital @2 Kumasi @3 GHA @Z 1 aut. @Z 3 aut.`
A14	`02`			`@1 Kwame Nkrumah University of Science and Technology @2 Kumasi @3 GHA @Z 1 aut. @Z 3 aut.`
A14	`03`			`@1 Wolfson Research Institute for Health and Wellbeing, Durham University @2 Stockton-on-Tees TS17 6BH @3 GBR @Z 2 aut.`
A14	`04`			`@1 Institute of Global Health, University of Liverpool @2 L69 7BE @3 GBR @Z 4 aut.`
A14	`05`			`@1 The James Cook University Hospital @2 Middlesbrough, TS4 3BW @3 GBR @Z 5 aut.`
A20				`@1 481-489`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18250 @5 354000504548680090`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 24 ref.`
A47	`01`	`1`		`@0 14-0264029`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 The Journal of infection`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 Objectives: To observe the long term response to first-line antiretroviral therapy (ART) in HIV and hepatitis B virus (HBV) co-infected patients in Ghana and explore predictors of poor clinical outcomes. Methods: Retrospective cohort study of hepatitis B surface antigen (HBsAg) positive and negative patients receiving predominantly NNRTI-based ART with lamivudine plus either zidovudine or stavudine for up to seven years. Cox proportional hazards and Kaplan Meier survival analyses compared clinical outcomes and identified baseline characteristics predictive of poor outcomes. A mixed effects model compared changes in CD4 counts. Results: A total of 299 HBsAg-positive and 1869 HBsAg-negative patients started ART between 2004 and 2008. Over a median 35 months of follow-up, HBsAg-positive patients were more likely to die or default care than HBsAg-negative patients, aHR 1.36 (95% CI, 1.03-1.80). HBsAg-positive patients were also more likely to develop Grade 3/4 hepatotoxicity than HBsAg-negative patients, HR 1.99 (1.16-3.40) on survival analysis. There was no significant difference in CD4 responses between HBsAg-positive and HBsAg-negative patients. Conclusions: HBsAg-positive patients are at significantly increased risk of adverse clinical outcomes after starting ART. Further studies are warranted to evaluate whether these risks remain now that tenofovir is becoming routinely available in Ghana.
C02	`01`	`X`		`@0 002B01`
C02	`02`	`X`		`@0 002B05C02D`
C02	`03`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 SIDA @5 01`
C03	`01`	`X`	`ENG`	`@0 AIDS @5 01`
C03	`01`	`X`	`SPA`	`@0 SIDA @5 01`
C03	`02`	`X`	`FRE`	`@0 Hépatite virale B @5 02`
C03	`02`	`X`	`ENG`	`@0 Viral hepatitis B @5 02`
C03	`02`	`X`	`SPA`	`@0 Hepatitis vírica B @5 02`
C03	`03`	`X`	`FRE`	`@0 Antiviral @5 04`
C03	`03`	`X`	`ENG`	`@0 Antiviral @5 04`
C03	`03`	`X`	`SPA`	`@0 Antiviral @5 04`
C03	`04`	`X`	`FRE`	`@0 Chimiothérapie @5 05`
C03	`04`	`X`	`ENG`	`@0 Chemotherapy @5 05`
C03	`04`	`X`	`SPA`	`@0 Quimioterapia @5 05`
C03	`05`	`X`	`FRE`	`@0 Long terme @5 07`
C03	`05`	`X`	`ENG`	`@0 Long term @5 07`
C03	`05`	`X`	`SPA`	`@0 Largo plazo @5 07`
C03	`06`	`X`	`FRE`	`@0 Antirétroviral @5 09`
C03	`06`	`X`	`ENG`	`@0 Antiretroviral agent @5 09`
C03	`06`	`X`	`SPA`	`@0 Antiretroviral @5 09`
C03	`07`	`X`	`FRE`	`@0 Virus immunodéficience humaine @2 NW @5 10`
C03	`07`	`X`	`ENG`	`@0 Human immunodeficiency virus @2 NW @5 10`
C03	`07`	`X`	`SPA`	`@0 Human immunodeficiency virus @2 NW @5 10`
C03	`08`	`X`	`FRE`	`@0 Ghana @2 NG @5 13`
C03	`08`	`X`	`ENG`	`@0 Ghana @2 NG @5 13`
C03	`08`	`X`	`SPA`	`@0 Ghana @2 NG @5 13`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Traitement`
C07	`03`	`X`	`ENG`	`@0 Treatment`
C07	`03`	`X`	`SPA`	`@0 Tratamiento`
C07	`04`	`X`	`FRE`	`@0 Lentivirus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Lentivirus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Lentivirus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Retroviridae @2 NW`
C07	`05`	`X`	`ENG`	`@0 Retroviridae @2 NW`
C07	`05`	`X`	`SPA`	`@0 Retroviridae @2 NW`
C07	`06`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`06`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`06`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`07`	`X`	`FRE`	`@0 Afrique @2 NG`
C07	`07`	`X`	`ENG`	`@0 Africa @2 NG`
C07	`07`	`X`	`SPA`	`@0 Africa @2 NG`
C07	`08`	`X`	`FRE`	`@0 Immunodéficit @5 37`
C07	`08`	`X`	`ENG`	`@0 Immune deficiency @5 37`
C07	`08`	`X`	`SPA`	`@0 Inmunodeficiencia @5 37`
C07	`09`	`X`	`FRE`	`@0 Immunopathologie @5 39`
C07	`09`	`X`	`ENG`	`@0 Immunopathology @5 39`
C07	`09`	`X`	`SPA`	`@0 Inmunopatología @5 39`
C07	`10`	`X`	`FRE`	`@0 Pathologie de l'appareil digestif @5 40`
C07	`10`	`X`	`ENG`	`@0 Digestive diseases @5 40`
C07	`10`	`X`	`SPA`	`@0 Aparato digestivo patología @5 40`
C07	`11`	`X`	`FRE`	`@0 Pathologie du foie @5 41`
C07	`11`	`X`	`ENG`	`@0 Hepatic disease @5 41`
C07	`11`	`X`	`SPA`	`@0 Hígado patología @5 41`
N21				`@1 328`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000001

Links to Exploration step

Pascal:14-0264029

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana</title>
<author><name sortKey="Sarfo, Fred Stephen" sort="Sarfo, Fred Stephen" uniqKey="Sarfo F" first="Fred Stephen" last="Sarfo">Fred Stephen Sarfo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Komfo Anokye Teaching Hospital</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Kwame Nkrumah University of Science and Technology</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Kasim, Adetayo" sort="Kasim, Adetayo" uniqKey="Kasim A" first="Adetayo" last="Kasim">Adetayo Kasim</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Wolfson Research Institute for Health and Wellbeing, Durham University</s1>
<s2>Stockton-on-Tees TS17 6BH</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Phillips, Richard" sort="Phillips, Richard" uniqKey="Phillips R" first="Richard" last="Phillips">Richard Phillips</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Komfo Anokye Teaching Hospital</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Kwame Nkrumah University of Science and Technology</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Geretti, Anna Maria" sort="Geretti, Anna Maria" uniqKey="Geretti A" first="Anna Maria" last="Geretti">Anna Maria Geretti</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institute of Global Health, University of Liverpool</s1>
<s2>L69 7BE</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Chadwick, David R" sort="Chadwick, David R" uniqKey="Chadwick D" first="David R." last="Chadwick">David R. Chadwick</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>The James Cook University Hospital</s1>
<s2>Middlesbrough, TS4 3BW</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0264029</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0264029 INIST</idno>
<idno type="RBID">Pascal:14-0264029</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000001</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000127</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana</title>
<author><name sortKey="Sarfo, Fred Stephen" sort="Sarfo, Fred Stephen" uniqKey="Sarfo F" first="Fred Stephen" last="Sarfo">Fred Stephen Sarfo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Komfo Anokye Teaching Hospital</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Kwame Nkrumah University of Science and Technology</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Kasim, Adetayo" sort="Kasim, Adetayo" uniqKey="Kasim A" first="Adetayo" last="Kasim">Adetayo Kasim</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Wolfson Research Institute for Health and Wellbeing, Durham University</s1>
<s2>Stockton-on-Tees TS17 6BH</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Phillips, Richard" sort="Phillips, Richard" uniqKey="Phillips R" first="Richard" last="Phillips">Richard Phillips</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Komfo Anokye Teaching Hospital</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Kwame Nkrumah University of Science and Technology</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Geretti, Anna Maria" sort="Geretti, Anna Maria" uniqKey="Geretti A" first="Anna Maria" last="Geretti">Anna Maria Geretti</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institute of Global Health, University of Liverpool</s1>
<s2>L69 7BE</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Chadwick, David R" sort="Chadwick, David R" uniqKey="Chadwick D" first="David R." last="Chadwick">David R. Chadwick</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>The James Cook University Hospital</s1>
<s2>Middlesbrough, TS4 3BW</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The Journal of infection</title>
<title level="j" type="abbreviated">J. infect.</title>
<idno type="ISSN">0163-4453</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The Journal of infection</title>
<title level="j" type="abbreviated">J. infect.</title>
<idno type="ISSN">0163-4453</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term>
<term>Antiretroviral agent</term>
<term>Antiviral</term>
<term>Chemotherapy</term>
<term>Ghana</term>
<term>Human immunodeficiency virus</term>
<term>Long term</term>
<term>Viral hepatitis B</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>SIDA</term>
<term>Hépatite virale B</term>
<term>Antiviral</term>
<term>Chimiothérapie</term>
<term>Long terme</term>
<term>Antirétroviral</term>
<term>Virus immunodéficience humaine</term>
<term>Ghana</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objectives: To observe the long term response to first-line antiretroviral therapy (ART) in HIV and hepatitis B virus (HBV) co-infected patients in Ghana and explore predictors of poor clinical outcomes. Methods: Retrospective cohort study of hepatitis B surface antigen (HBsAg) positive and negative patients receiving predominantly NNRTI-based ART with lamivudine plus either zidovudine or stavudine for up to seven years. Cox proportional hazards and Kaplan Meier survival analyses compared clinical outcomes and identified baseline characteristics predictive of poor outcomes. A mixed effects model compared changes in CD4 counts. Results: A total of 299 HBsAg-positive and 1869 HBsAg-negative patients started ART between 2004 and 2008. Over a median 35 months of follow-up, HBsAg-positive patients were more likely to die or default care than HBsAg-negative patients, aHR 1.36 (95% CI, 1.03-1.80). HBsAg-positive patients were also more likely to develop Grade 3/4 hepatotoxicity than HBsAg-negative patients, HR 1.99 (1.16-3.40) on survival analysis. There was no significant difference in CD4 responses between HBsAg-positive and HBsAg-negative patients. Conclusions: HBsAg-positive patients are at significantly increased risk of adverse clinical outcomes after starting ART. Further studies are warranted to evaluate whether these risks remain now that tenofovir is becoming routinely available in Ghana.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0163-4453</s0>
</fA01>
<fA02 i1="01"><s0>JINFD2</s0>
</fA02>
<fA03 i2="1"><s0>J. infect.</s0>
</fA03>
<fA05><s2>69</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SARFO (Fred Stephen)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KASIM (Adetayo)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PHILLIPS (Richard)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GERETTI (Anna Maria)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>CHADWICK (David R.)</s1>
</fA11>
<fA14 i1="01"><s1>Komfo Anokye Teaching Hospital</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Kwame Nkrumah University of Science and Technology</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Wolfson Research Institute for Health and Wellbeing, Durham University</s1>
<s2>Stockton-on-Tees TS17 6BH</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Institute of Global Health, University of Liverpool</s1>
<s2>L69 7BE</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>The James Cook University Hospital</s1>
<s2>Middlesbrough, TS4 3BW</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>481-489</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18250</s2>
<s5>354000504548680090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>24 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0264029</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The Journal of infection</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objectives: To observe the long term response to first-line antiretroviral therapy (ART) in HIV and hepatitis B virus (HBV) co-infected patients in Ghana and explore predictors of poor clinical outcomes. Methods: Retrospective cohort study of hepatitis B surface antigen (HBsAg) positive and negative patients receiving predominantly NNRTI-based ART with lamivudine plus either zidovudine or stavudine for up to seven years. Cox proportional hazards and Kaplan Meier survival analyses compared clinical outcomes and identified baseline characteristics predictive of poor outcomes. A mixed effects model compared changes in CD4 counts. Results: A total of 299 HBsAg-positive and 1869 HBsAg-negative patients started ART between 2004 and 2008. Over a median 35 months of follow-up, HBsAg-positive patients were more likely to die or default care than HBsAg-negative patients, aHR 1.36 (95% CI, 1.03-1.80). HBsAg-positive patients were also more likely to develop Grade 3/4 hepatotoxicity than HBsAg-negative patients, HR 1.99 (1.16-3.40) on survival analysis. There was no significant difference in CD4 responses between HBsAg-positive and HBsAg-negative patients. Conclusions: HBsAg-positive patients are at significantly increased risk of adverse clinical outcomes after starting ART. Further studies are warranted to evaluate whether these risks remain now that tenofovir is becoming routinely available in Ghana.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B01</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02D</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>SIDA</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>AIDS</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>SIDA</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Hépatite virale B</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Viral hepatitis B</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Hepatitis vírica B</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Long terme</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Long term</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antirétroviral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antiretroviral agent</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiretroviral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Virus immunodéficience humaine</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Ghana</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Ghana</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Ghana</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Afrique</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Africa</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Africa</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Immunodéficit</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Immune deficiency</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Inmunodeficiencia</s0>
<s5>37</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Immunopathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Immunopathology</s0>
<s5>39</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Inmunopatología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Pathologie de l'appareil digestif</s0>
<s5>40</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Digestive diseases</s0>
<s5>40</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Aparato digestivo patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Pathologie du foie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Hepatic disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Hígado patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>328</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000127 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000127 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaGhanaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:14-0264029
   |texte=   Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana
}}

This area was generated with Dilib version V0.6.31.
Data generation: Tue Nov 7 18:07:38 2017. Site generation: Tue Mar 5 15:01:57 2024

	Le SIDA au Ghana (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Le SIDA au Ghana (serveur d'exploration)

Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana

Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri